No Data
DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Market Cap Increased by CN¥649m, Insiders Receive a 65% Cut
DaShenLin Pharmaceutical Group (603233.SH): Plans to adjust the investment scale of the "Nam Cheong DaShenLin Industrial Base Project (Phase I)" and its completion.
On December 10, Gelonghui reported that DaShenLin Pharmaceutical Group (603233.SH) announced plans to adjust the investment scale and project completion of the "Nam Cheong DaShenLin Industrial Base Project (Phase One)". The project plans to use raised funds of 128.1401 million yuan, with actual raised fund usage of 67.262 million yuan, and the remaining raised funds (as of November 28, 2024, actual balance of the raised funds account is 65.8996 million yuan, including interest income, etc.) will be permanently added to working capital.
Is DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
China Merchants Securities: Establishment of prepayment policy for medical insurance funds, releasing incremental signals at the bottom of the pharmaceutical sector.
It is reported that standardized prepayment process management, with the scale of regional prepayment in line with the approved standards for about one month, the prepayment system effectively alleviates the financial pressure of medical institutions, empowering the medical and pharmaceutical industry.
DaShenLin Pharmaceutical Group (SHSE:603233) Could Be Struggling To Allocate Capital
Dashanlin: Dashanlin Pharmaceutical Group Co., Ltd. Third Quarter Report 2024
